The schizophrenia spectrum anhedonia paradox

Strauss, Gregory P.; Cohen, Alex S.

doi:10.1002/wps.20529

Cited by 28 publications

(24 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The internal consistency of anhedonia in general could have been problematic, because its independence from depressive symptomatology was not clear with the design applied [67]. It is also possible that stress attenuates the reward system response [68] precisely when studied in youths in the general population. Furthermore, the reliability found in the diminished emotional range factor could be affected by defining indicators that require either observation by others (Item 5 considers the point of view of others) or good capacity for self-evaluation by the adolescent.…”

Section: Discussionmentioning

confidence: 99%

Spanish validation of the self-evaluation of negative symptoms scale SNS in an adolescent population

et al. 2019

View full text Add to dashboard Cite

BackgroundNegative symptoms (NS) may be observed in the general population in an attenuated form and in high-risk mental states. However, they have been less studied in the general population than positive symptoms, in spite of their importance at the insidious onset of schizophrenia and their appearance before positive symptoms. This study aimed to analyze the empirical structure of the Spanish version of the Self-Evaluation of Negative Symptoms (SNS) Scale and find its psychometric properties and invariance of measurement across sex and age in a sample of adolescents.MethodsThe sample consisted of 4521 adolescents (53.6% female) from 11 to 18 years of age.ResultsConfirmatory Factor Analysis of the SNS confirmed an internal structure of five first-order factors by the characteristic dimensions of NS: avolition, social withdrawal, diminished emotional range, anhedonia, alogia, and one second-order factor which includes the total NS score. Multi-group confirmatory factor analysis showed that the scale was invariant across sex and age. Total scale reliability was adequate. A strong relationship was found between the SNS with depressive symptomatology, moderate with ideas of reference and low with aberrant salience. Conclusion: The results back use of the Spanish version of the SNS scale for detection of NS in the general population of adolescents.

show abstract

Section: Discussionmentioning

confidence: 99%

Spanish validation of the self-evaluation of negative symptoms scale SNS in an adolescent population

et al. 2019

View full text Add to dashboard Cite

show abstract

“…However, an important difference in anhedonia in depression and psychosis is not commonly assessed in these measures. A recent review highlights that people with psychosis do not experience a reduction in their capacity to experience pleasure (Strauss and Cohen, 2018), whereas this is commonly seen in people with depression and described as anhedonia. Unfortunately, the subscales reported in the depression measures included are not detailed enough to analyse this difference in our findings, but it should be considered in future research.…”

Section: Discussionmentioning

confidence: 99%

The relationship between depressive symptoms and negative symptoms in people with non-affective psychosis: a meta-analysis

2019

View full text Add to dashboard Cite

The negative symptoms of psychosis and depressive symptomatology share several features, e.g. low motivation, apathy and reduced activity. Understanding the associations between these two sets of symptoms will support improved assessment and the development of interventions targeting these difficulties in people with psychosis. This is the first large systematic review and meta-analysis to quantify the relationship between these two categories of symptoms, as measured in studies to date. PsycInfo, Embase and Medline were systematically searched to identify eligible studies. Inclusion criteria ensured the studies measured both depression and negative symptoms using validated measures in a sample of over 8000 participants with non-affective psychosis diagnoses. The search led to 2020 records being screened and 56 included in the meta-analysis and review. Both meta-analyses and meta-regressions were conducted to explore the main effect and potential moderating variables. A clear pattern emerges showing that higher ratings of negative symptoms are associated with higher levels of depressive symptoms, with a small effect [standardised effect size = 0.19, p < 0.05). This did not vary greatly with the measures used (SES = 0.19–0.26) and was not moderated by demographic variables or quality ratings. Interestingly, higher depressive symptoms predict a significant relationship with co-occurring negative symptoms. However, higher negative symptoms predict that it is less likely there will be a relationship with co-occurring depressive symptoms. Heterogeneity was high across these analyses. The findings support the adoption of a symptom-specific approach to understanding the interplay between negative and depressive symptoms in psychosis, to improve assessment and intervention.

show abstract

“…Further complicating the picture, individuals might have deficits in one area but be relatively intact in another. For instance, anhedonia in schizophrenic populations is largely characterized by deficits in anticipatory pleasure but not consummatory pleasure, such that the extent of engagement in pleasurable activities does not necessarily reflect reduced hedonic capacity (Strauss & Cohen, 2018; Strauss & Gold, 2012). The concept of anhedonia is also distinct from negative affect or dysphoria.…”

Section: Anhedonia Definition and Measurementmentioning

confidence: 99%

Anhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder

Kiluk

Yip

DeVito

et al. 2019

Clinical Psychological Science

View full text Add to dashboard Cite

There is a critical need for research on clinical features that may influence response to treatment for opioid use disorder (OUD). Given its neurobiology and relevance to opioid use, anhedonia may be one such promising clinical feature. We identified and reviewed 11 studies that measured anhedonia in humans with OUD to characterize the current state of evidence and highlight potential implications for treatment. The majority of studies were cross-sectional, indicating higher anhedonia scores in opioid-dependent samples compared with healthy control subjects. Rates of participants with clinically significant anhedonia ranged from 21% to 48%. Anhedonia scores were correlated with opioid craving and use; however, there are significant knowledge gaps regarding its time course and impact on treatment adherence and outcomes. Repeated assessment of anhedonia early in treatment for OUD is recommended because it may be a unique predictor of dropout or nonresponse and a potential target for behavioral and/or pharmacological intervention.

show abstract

The schizophrenia spectrum anhedonia paradox

Cited by 28 publications

References 12 publications

Spanish validation of the self-evaluation of negative symptoms scale SNS in an adolescent population

Spanish validation of the self-evaluation of negative symptoms scale SNS in an adolescent population

The relationship between depressive symptoms and negative symptoms in people with non-affective psychosis: a meta-analysis

Anhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder

Contact Info

Product

Resources

About